Research programme: retinal degeneration therapeutics - BioTime/University of Pittsburgh Medical Center

Drug Profile

Research programme: retinal degeneration therapeutics - BioTime/University of Pittsburgh Medical Center

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pittsburgh Medical Center
  • Developer BioTime
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Retinal disorders

Most Recent Events

  • 17 Jan 2018 BioTime has patent protection for Pluripotent cell technology in USA, Japan, Singapore, India and Europe
  • 18 Sep 2017 BioTime receives SBIR grant from National Institutes of Health for retinal degeneration therapeutics development
  • 06 Feb 2017 BioTime in-licenses Retinal tissue implant technology from University of Pittsburgh Medical Center
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top